Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
about
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapyUnderstanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?c-Met as a Target for Personalized TherapyHepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer ChallengeGenetic and Chromosomal Aberrations and Their Clinical Significance in Renal NeoplasmsTherapeutic challenges in renal cell carcinomaMet in urological cancersPhase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerCIViC databaseThe AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerClinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selectionRoles of c-Met and RON kinases in tumor progression and their potential as therapeutic targetsA human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinomaA first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation studyForetinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-MetRON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cellsThe potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia.Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches.Targeting MET Amplification as a New Oncogenic Driver.Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines.Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategiesMultitarget inhibitors derived from crosstalk mechanism involving VEGFR2.Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular proteinSpectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients.Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma.Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.MET is required for the recruitment of anti-tumoural neutrophilsNon-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma.Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeuticsc-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinomaComprehensive Molecular Characterization of Papillary Renal-Cell CarcinomaPhase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.
P2860
Q26741450-5A138DB7-0705-4E7B-8E9B-CD3C5C0DA6B1Q26748581-8505BC22-3440-4B78-8783-30F5FF58C698Q26775483-DDBFA6C4-BBE0-47B9-AA0F-DCFD11E871DBQ26781273-039593B0-D474-4AB2-BB2F-E947AD384B46Q26785930-3541C6DD-F7C2-4981-A103-7A3829674991Q26796702-93CAB077-8888-4C07-A85F-39CA0BAA3333Q26864988-F73051B5-5765-4A22-B690-AC42B2DBE7DBQ27320322-F12E5661-A543-412A-8088-DAC299E904F7Q27612411-6CC09352-B87A-4407-BBFB-614C0473DDE3Q27853383-2354F86C-61DE-4997-973C-17A4A53C710BQ28067777-B61E0E54-D1A5-4D9B-B2FE-E182E6688BDBQ28074834-3BD24674-AD93-4881-8E59-736CF1CF7676Q28081193-6521B4AE-2856-4634-9693-9B238EA43E2DQ28487973-87C3F132-0673-4404-9F3A-60C0CD19ACD6Q33424270-117D6E3E-4B76-4D25-BF91-CE18F14CC8D2Q33577856-9F00898D-93D5-464D-990D-13EE2447E9CCQ33702320-5BB0FC03-59D5-45FE-BD7E-105AE776F4E1Q33721142-9187B975-5151-45A0-9AA5-197D00770304Q33769429-90BE26CC-6CE9-4F7A-B79C-4CC6255E547CQ33769437-209EEAF4-3A2E-424F-AA42-8F8C266B8E51Q33946966-3D87066B-862A-43AC-934F-7250DCDD88AFQ34194075-694BD4F4-6581-4348-95EB-2D17110D8C3FQ34309927-7647AABB-4E19-465B-A8B5-CA8201123BA6Q34996693-918F718B-B30F-4A63-AED8-65932D3CF606Q35315403-7DA0F38D-FDBE-4E61-8E8C-0D44A1FDE87DQ35434188-F7017D75-11FF-4E61-8192-0EAF66E5689AQ35747784-3F0BF307-89B9-44B6-BF7B-AFF9B2E5EB3AQ35810625-779BD955-209E-4952-A5F6-260348BF6594Q35861046-3E19712C-EAE1-4975-A7BF-735BBFBDBDC4Q35955290-2BB0806B-366A-4B0C-994F-ECC79FB9A37CQ36020888-D0F68221-2359-4950-9E48-31F8DBFA143EQ36125652-98D70862-BF80-476D-8BE9-4735CE931784Q36182819-94C2F936-399E-4C4B-ABE1-BADC941C88F6Q36214648-06313C55-A169-4915-9539-FBCD477FC0CEQ36354841-21641538-7894-45F1-BCCD-2D832ED106B7Q36544653-8020D693-D059-42AF-B03F-A1D24CFDBDA8Q36551653-6E9D3A0C-D76C-4ECF-BA25-F315029AE7DDQ36642291-2EC1FEEF-F9B2-4D57-8E59-A160F221B901Q36660533-AC363621-F44D-4253-AD52-825E6DA92ED5Q36693159-6E41B287-4AEF-496E-B09D-7A4A05ECD4CE
P2860
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase II and biomarker study o ...... papillary renal cell carcinoma
@ast
Phase II and biomarker study o ...... papillary renal cell carcinoma
@en
Phase II and biomarker study o ...... apillary renal cell carcinoma.
@nl
type
label
Phase II and biomarker study o ...... papillary renal cell carcinoma
@ast
Phase II and biomarker study o ...... papillary renal cell carcinoma
@en
Phase II and biomarker study o ...... apillary renal cell carcinoma.
@nl
altLabel
Phase II and Biomarker Study o ...... Papillary Renal Cell Carcinoma
@en
prefLabel
Phase II and biomarker study o ...... papillary renal cell carcinoma
@ast
Phase II and biomarker study o ...... papillary renal cell carcinoma
@en
Phase II and biomarker study o ...... apillary renal cell carcinoma.
@nl
P2093
P2860
P3181
P356
P1476
Phase II and biomarker study o ...... papillary renal cell carcinoma
@en
P2093
Andrea L Harzstark
Brian I Rini
David F McDermott
Donald P Bottaro
Jonathan E Rosenberg
Kevin H Laubscher
Laurel M Adams
Laurie Sherman
Lone H Ottesen
Maria J Merino
P2860
P3181
P356
10.1200/JCO.2012.43.3383
P407
P577
2013-01-10T00:00:00Z